Market Closed - Bombay S.E. Other stock markets | 5-day change | 1st Jan Change | ||
5,884 INR | +0.34% | | +1.20% | +1.49% |
12:16pm | Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research | RE |
05-24 | Dr. Reddy's Laboratories LLC, Russia Enters into Distribution Agreement with Novartis Pharma LLC | CI |
January 28, 2019 at 02:48 am
Dr. Reddy's Laboratories Ltd. and its subsidiary, Promius Pharma, LLC announced the approval of TOSYMRA (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). TOSYMRA is indicated for the acute treatment of migraine with or without aura in adults. TOSYMRA is the latest product to join the Promius Pharma acute migraine treatment portfolio. The company is working toward commercialization of this product.
Share
© S&P Capital IQ - 2019
Latest news about Dr. Reddy's Laboratories Limited
Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research | RE | |
Dr. Reddy's Laboratories LLC, Russia Enters into Distribution Agreement with Novartis Pharma LLC | CI | |
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower | MT | |
Dr. Reddy's Laboratories Limited Informed That the Company Has Received an Order from GST Authority Towards Tax Demand Including Interest and Penalty | CI | |
Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading | MT | |
Indian shares set to rise at open; Fed minutes eyed | RE | |
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading | MT | |
Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab | MT | |
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher | MT | |
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading | MT | |
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading | MT | |
Asian Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading | MT | |
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher | MT | |
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week 1% Lower | MT | |
Asian Equities Traded in the US as American Depositary Receipts Trend Lower Thursday | MT | |
India's Alembic Pharma posts higher Q4 profit on strong N.America sales | RE | |
Asian Equities Traded in the US as American Depositary Receipts Trend Slightly Lower in Wednesday Trading | MT | |
Indian Equities Settle Flat on Wednesday, Dragged by Banks, FMCG Stocks | MT | |
Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR5,010 From INR5,040, Keeps at Underperform | MT | |
Dr. Reddy's Consolidated Net Profit Jumps in Fiscal Q4; Shares Slide 3% | MT | |
Asian Equities Traded in the US as American Depositary Receipts Drop Sharply in Tuesday Trading | MT | |
Transcript : Dr. Reddy's Laboratories Limited, Q4 2024 Earnings Call, May 07, 2024 | ||
Dr. Reddy's Laboratories Fiscal Q4 Earnings, Revenue Gain | MT | |
India's Dr Reddy's beats Q4 profit estimates | RE | |
Dr. Reddy's Laboratories Limited Announces Cessation of Parag Agarwal as Member of Management Council | CI |
Chart Dr. Reddy's Laboratories Limited
More charts
Company Profile
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
15/07/2024 - Ex-dividend day for final dividend
Related indices
NIFTY 50 , NIFTY 100
More about the company
Income Statement Evolution
More financial data
Ratings for Dr. Reddy's Laboratories Limited
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
5,884INR
Average target price
6,101INR
Spread / Average Target
+3.68%
Consensus
EPS Revisions
Estimates Revisions
Quarterly earnings - Rate of surprise
Company calendar
Sector Other Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
DR. REDDY'S LABORATORIES LIMITED | +1.49% | 11.76B |
ELI LILLY AND COMPANY | +38.51% | 727B |
NOVO NORDISK A/S | +31.74% | 599B |
-6.23% | 354B | |
+18.78% | 328B | |
ABBVIE INC. | +1.35% | 277B |
ASTRAZENECA PLC | +16.00% | 243B |
NOVARTIS AG | +8.44% | 205B |
ROCHE HOLDING AG | -5.97% | 203B |
AMGEN INC. | +6.19% | 164B |
Other Pharmaceuticals
- Stock Market
- Equities
- DRREDDY Stock
- News Dr. Reddy's Laboratories Limited
- Dr. Reddy's Laboratories and Promius Pharma, Announces FDA Approval for TOSYMRA (Sumatriptan Nasal Spray) 10mg, in the U.S. Market